Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) COO Colin Love sold 17,615 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total transaction of $113,969.05. Following the transaction, the chief operating officer now directly owns 777,345 shares in the company, […]
Replimune Group (NASDAQ:REPL – Free Report) had its target price decreased by Barclays from $50.00 to $13.00 in a research report report published on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other brokerages also recently weighed in on REPL. Wedbush reaffirmed an outperform rating and issued […]
Camber Capital Management LP increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 24.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,550,000 shares of the company’s stock after acquiring an additional 300,000 shares […]
Mirae Asset Global Investments Co. Ltd. boosted its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 6.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,226 shares of the company’s stock after purchasing an additional 1,649 shares […]
Replimune Group (NASDAQ:REPL – Free Report) had its price target reduced by HC Wainwright from $51.00 to $50.00 in a report published on Monday, MarketBeat.com reports. They currently have a buy rating on the stock. Separately, Piper Sandler reiterated an overweight rating and issued a $44.00 target price on shares of Replimune Group in a […]
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock […]
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock […]
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock […]